Skip to main content
All lobbying filings

FAEGRE DRINKER BIDDLE & REATH LLP

Lobbying for TEVA PHARMACEUTICALS USA, INC. · Pharmaceutical manufacturer

 Filing 1st Quarter - Report
Reporting period
1st Quarter 2025
Jan 1 - Mar 31 · Posted Apr 18, 2025
Income
$60,000.00
What the client paid this registrant for the period.
Client based in
New Jersey

Official filing document

 Lobbyists on this filing 3
  • MEGAN SUSSMAN HERBER
    Previously held: Press Secretary and Legislative Assistant, Rep. Christopher H. Smith (R-NJ)
  • ELLIOT VICE
    Previously held: Staff Assistant, Legislative Correspondent & Scheduler, Sen. Evan Bayh (D-IN) 2009-2010
  • BRYAN MICHAEL ALLEN
    Previously held: Staff Assistant, Legislative Correspondent, Legislative Aide, Sen. Susan Collins (R-ME)

A "covered position" is a government job the lobbyist held in the 20 years before registering, which the law requires them to name. See the revolving door for former members of Congress across all filings.

 Government bodies contacted 2
  • HOUSE OF REPRESENTATIVES
  • SENATE

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

 Bills named in this filing 1
  • HR 1843
    To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.
 Lobbying activity 2
Health Issues

Skinny Labels, Big Savings Act (S 43). Changes to Hatch-Waxmans 180-day exclusivity incentive. Changes to FDA approval process for pharmaceuticals (S 1096, HR 1843). Implementation of Inflation Reduction Act pricing proposal. Oversight and reform efforts affecting pharmacy benefit managers. Patent reform (S 1095, S 1097). Proposals related to drug shortages. Proposals related to pharmaceutical tariffs.

Copyright/Patent/Trademark

Skinny Labels, Big Savings Act (S 43). Changes to Hatch-Waxmans 180-day exclusivity incentive. Changes to FDA approval process for pharmaceuticals (S 1096, HR 1843). Implementation of Inflation Reduction Act pricing proposal. Oversight and reform efforts affecting pharmacy benefit managers. Patent reform (S 1095, S 1097). Proposals related to drug shortages. Proposals related to pharmaceutical tariffs.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem